Constantine Mitsiades

List of Publications by Year
in descending order

74	10,899	47006 47	91884 69
papers	citations	h-index	g-index

77	77	77	9868
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	NF-ÎºB as a Therapeutic Target in Multiple Myeloma. Journal of Biological Chemistry, 2002, 277, 16639-16647.	3.4	824
2	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 2007, 7, 585-598.	28.4	817
3	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100, 3063-3067.	1.4	759
4	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8, 407-419.	16.8	673
5	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101, 1530-1534.	1.4	533
6	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 2001, 98, 428-435.	1.4	399
7	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107, 4053-4062.	1.4	398
8	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood, 2007, 109, 3177-3188.	1.4	379
9	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 2009, 114, 371-379.	1.4	364
10	Bortezomib induces canonical nuclear factor-ÎºB activation in multiple myeloma cells. Blood, 2009, 114, 1046-1052.	1.4	329
11	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. Annual Review of Medicine, 2006, 57, 33-47.	12.2	317
12	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood, 2004, 103, 1787-1790.	1.4	266
13	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. Cancer Cell, 2009, 16, 309-323.	16.8	242
14	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. Journal of Clinical Oncology, 2009, 27, 3518-3525.	1.6	241
15	The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development. Current Cancer Drug Targets, 2004, 4, 235-256.	1.6	240
16	Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood, 2003, 102, 4504-4511.	1.4	212
17	Targeting the Î²-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7516-7521.	7.1	197
18	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia and Lymphoma, 2008, 49, 502-507.	1.3	185

#	Article	IF	Citations
19	JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells. Journal of Biological Chemistry, 2003, 278, 17593-17596.	3.4	180
20	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 2004, 104, 4188-4193.	1.4	177
21	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene, 2003, 22, 8386-8393.	5.9	163
22	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Research, 2003, 63, 5850-8.	0.9	159
23	Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics, 2005, 4, 686-692.	4.1	148
24	Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 2003, 102, 3379-3386.	1.4	147
25	New Drugs for Myeloma. Oncologist, 2007, 12, 664-689.	3.7	145
26	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood, 2007, 109, 1220-1227.	1.4	144
27	MLN120B, a Novel IÎºB Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clinical Cancer Research, 2006, 12, 5887-5894.	7.0	130
28	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 2004, 23, 8766-8776.	5.9	127
29	Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood, 2004, 103, 1799-1806.	1.4	127
30	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic antiâ€“multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 2004, 103, 3158-3166.	1.4	122
31	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. Mayo Clinic Proceedings, 2004, 79, 875-882.	3.0	120
32	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3â€“kinase/AKT/NF-ÎºB signaling. Blood, 2003, 101, 2762-2769.	1.4	111
33	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. British Journal of Haematology, 2007, 138, 783-791.	2.5	102
34	Gene expression analysis of Bâ€lymphoma cells resistant and sensitive to bortezomib*. British Journal of Haematology, 2006, 134, 145-156.	2.5	94
35	Proteasome Inhibition in the Treatment of Cancer. Cell Cycle, 2005, 4, 289-295.	2.6	92
36	New Proteasome Inhibitors in Myeloma. Current Hematologic Malignancy Reports, 2012, 7, 258-266.	2.3	89

#	Article	IF	Citations
37	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood, 2004, 104, 2458-2466.	1.4	79
38	Bortezomib in the front-line treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2008, 8, 1053-1072.	2.4	79
39	Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics, 2007, 6, 1951-1961.	4.1	78
40	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood, 2003, 101, 3606-3614.	1.4	67
41	Proteasome inhibition in hematologic malignancies. Annals of Medicine, 2004, 36, 304-314.	3.8	59
42	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 149-162.	4.9	59
43	A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood, 2010, 115, 3772-3775.	1.4	56
44	Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene, 2004, 23, 3597-3602.	5.9	54
45	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Research, 2003, 63, 8428-36.	0.9	54
46	The Treatment of Relapsed and Refractory Multiple Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 317-323.	2.5	53
47	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37.	7.2	51
48	Lenalidomide in multiple myeloma. Expert Review of Anticancer Therapy, 2006, 6, 1165-1173.	2.4	50
49	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-Î² inhibitors. Oncogene, 2005, 24, 3121-3129.	5.9	43
50	Proteasome inhibition in the treatment of cancer. Cell Cycle, 2005, 4, 290-6.	2.6	42
51	Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies. Current Drug Targets, 2006, 7, 1341-1347.	2.1	40
52	Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncology, 2005, 1, 161-167.	2.4	33
53	Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-4-S-12.	4.9	33
54	A novel panel of protein biomarkers for predicting response to thalidomideâ€based therapy in newly diagnosed multiple myeloma patients. Proteomics, 2011, 11, 1391-1402.	2.2	33

#	Article	IF	Citations
55	The power of proteasome inhibition in multiple myeloma. Expert Review of Proteomics, 2018, 15, 1033-1052.	3.0	33
56	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Current Opinion in Oncology, 2006, 18, 598-608.	2.4	32
57	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Management and Research, 2012, 4, 253.	1.9	28
58	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evidence, 2010, 4, 215.	4.7	18
59	Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. Clinical Cancer Research, 2014, 20, 5483-5495.	7.0	16
60	A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. European Journal of Medicinal Chemistry, 2021, 219, 113435.	5.5	15
61	Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.. Blood, 2006, 108, 88-88.	1.4	13
62	Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs, 2007, 12, 155-163.	2.4	11
63	Targeting Bcl-2 as Therapy for Multiple Myeloma.. Blood, 2005, 106, 109-109.	1.4	5
64	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.. Blood, 2004, 104, 785-785.	1.4	4
65	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. Blood, 2004, 104, 2405-2405.	1.4	3
66	Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nature Clinical Practice Oncology, 2008, 5, 374-375.	4.3	2
67	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. Expert Opinion on Orphan Drugs, 2014, 2, 1089-1108.	0.8	1
68	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. Blood, 2005, 106, 3378-3378.	1.4	1
69	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. Blood, 2004, 104, 285-285.	1.4	1
70	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. Clinical Lymphoma and Myeloma, 2009, 9, S40-S42.	1.4	0
71	Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	1.4	0
72	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. Blood, 2004, 104, 764-764.	1.4	0

#	Article	IF	Citations
73	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood, 2008, 112, 2737-2737.	1.4	0
74	Novel Agents in Multiple Myeloma. , 2013, , 215-228.		0